Teva withdraws US challenge to Merck & Co's Singulair patent
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has withdrawn its appeal of a US district court ruling from last summer that upheld Merck & Co's compound patent on its top-selling asthma drug, Singulair (montelukast sodium), according to court documents. Merck is expected to maintain a hold on its franchise in the US until 2012.